Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial

American Journal of Psychiatry

Volumn 175, Issue 4, 2018, Pages 327-335

  Grunebaum, Michael F ^a   Galfalvy, Hanga C ^a   Choo, Tse Hwei ^a   Keilp, John G ^a   Moitra, Vivek K ^a   Parris, Michelle S ^a   Marver, Julia E ^a   Burke, Ainsley K ^a   Milak, Matthew S ^a   Sublette, M Elizabeth ^a   Oquendo, Maria A ^a   Mann, J John ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MIDAZOLAM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR SUICIDAL IDEATION SCORE; SCORING SYSTEM; SUICIDAL IDEATION; TREATMENT OUTCOME; BEHAVIOR ASSESSMENT; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGY; SUICIDE; YOUNG ADULT;

ADULT; BEHAVIOR RATING SCALE; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDAZOLAM; MIDDLE AGED; SUICIDAL IDEATION; SUICIDE; YOUNG ADULT;

EID: 85044840394     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17060647     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention (CDC): Fatal Injury Reports, National, Regional, and State, 1981-2015.Atlanta, CDC, Webbased Injury Statistics Query and Reporting System (WISQARS) https://webappa.cdc.gov/sasweb/ncipc/mortrate.html.
2. American Psychiatric Association: Practice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors. Washington, DC, American Psychiatric Association, 2003. http://psychiatryonline.org/pb/assets/raw/sitewide/practice-guidelines/guidelines/suicide.pdf.
3. Gibbons RD, Brown CH, Hur K, et al: Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:580-587.
4. Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91.
5. Prudic J, Sackeim HA: Electroconvulsive therapy and suicide risk. J Clin Psychiatry 1999; 60(suppl 2):104-110.
6. Cipriani A, Hawton K, Stockton S, et al: Lithium in the prevention of suicide in mood disorders: updated systematic review and metaanalysis. BMJ 2013; 346:f3646.
7. Trivedi MH, Rush AJ, Wisniewski SR, et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40.
8. Mann JJ, Apter A, Bertolote J, et al: Suicide prevention strategies: A systematic review. JAMA 2005; 294:2064-2074.
9. Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159:469-473.
10. Nock MK, Hwang I, Sampson NA, et al: Mental disorders, comorbidity, and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15:868-876.
11. Newport DJ, Carpenter LL, McDonald WM, et al: Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172:950-966.
12. Berman RM, Cappiello A, Anand A, et al: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47:351-354.
13. Zarate CA Jr, Singh JB, Carlson PJ, et al: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856-864.
14. KudohA, Takahira Y, Katagai H, et al: Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95: 114-118.
15. Price RB, NockMK, Charney DS, et al: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66:522-526.
16. DiazGranados N, Ibrahim LA, Brutsche NE, et al: Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71:1605-1611.
17. Ionescu DF, Swee MB, Pavone KJ, et al: Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 2016; 77:e719-e725.
18. Price RB, Iosifescu DV, Murrough JW, et al: Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014; 31: 335-343.
19. Murrough JW, Soleimani L, DeWilde KE, et al: Ketamine for rapid reduction of suicidal ideation: A randomized controlled trial. Psychol Med 2015; 45:3571-3580.
20. Beck AT, Kovacs M, Weissman A: Assessment of suicidal intention: The Scale for Suicide Ideation. J Consult Clin Psychol 1979; 47: 343-352.
21. Murrough JW, Iosifescu DV, Chang LC, et al: Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 2013; 170:1134-1142.
22. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
23. Brown GK, Beck AT, Steer RA, et al: Risk factors for suicide in psychiatric outpatients: A 20-year prospective study. J Consult Clin Psychol 2000; 68:371-377.
24. Holi MM, Pelkonen M, Karlsson L, et al: Psychometric properties and clinical utility of the Scale for Suicidal Ideation (SSI) in adolescents. BMC Psychiatry 2005; 5:8.
25. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
26. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, New York State Psychiatric Institute, Biometrics Research Department, 1994.
27. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (Version 2.0). New York, New York State Psychiatric Institute, Biometrics Research Department, 1996.
28. Beck AT, Brown GK, Steer RA: Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. Behav Res Ther 1997; 35:1039-1046.
29. Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571.
30. McNair DM, Lorr M, Droppleman LF: Manual for the Profile of Mood States. San Diego, Educational and Industrial Testing Service, 1981.
31. Levine J, Schooler NR: SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22:343-381.
32. Bremner JD, Krystal JH, Putnam FW, et al: Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11:125-136.
33. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812.
34. Grunebaum MF, Ellis SP, Duan N, et al: Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology 2012; 37: 697-706.
35. Witte TK, Joiner TE Jr, Brown GK, et al: Factors of suicide ideation and their relation to clinical and other indicators in older adults. J Affect Disord 2006; 94:165-172.
36. Muthén LK, Muthén BO: Mplus User's Guide, 7th ed. Los Angeles, Muthén & Muthén, 2012.
37. Sanacora G, Frye MA, McDonald W, et al:AConsensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74:399-405.
38. Restifo E, Kashyap S, Hooke GR, et al: Daily monitoring of temporal trajectories of suicidal ideation predict self-injury: A novel application of patient progress monitoring. Psychother Res 2015; 25:705-713.
39. Thase ME: The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists? Curr Psychiatry Rep 2011; 13:476-482.
40. National Institute for Health and Care Excellence: Depression in Adults: Recognition and Management (Clinical Guideline 90). London, National Institute for Health and Care Excellence, 2009.
41. Hu YD, Xiang YT, Fang JX, et al: Single iv ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 2016; 46:623-635.
42. Murrough JW, Abdallah CG, Mathew SJ: Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov 2017; 16:472-486.
43. Keilp JG, Grunebaum MF, Gorlyn M, et al: Suicidal ideation and the subjective aspects of depression. J Affect Disord 2012; 140:75-81.
44. Duman RS, Aghajanian GK, Sanacora G, et al: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22:238-249.
45. Beck AT, Steer RA, Ranieri WF: Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol 1988; 44: 499-505.
46. Carmody TJ, Rush AJ, Bernstein I, et al: The Montgomery Asberg and the Hamilton ratings of depression: A comparison of measures. Eur Neuropsychopharmacol 2006; 16:601-611.
47. Oquendo MA, Galfalvy HC, Russo S, et al: Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry 2004; 161:1433-1441.
48. Oquendo MA, Halberstam B, Mann JJ: Risk Factors for Suicidal Behavior: utility and limitations of research instruments, in Standardized Evaluation in Clinical Practice. Edited by First MB. Washington, DC, American Psychiatric Publishing, 2003, pp103-130.